Benefits
Energy Production
Thiamine is a coenzyme in carbohydrate metabolism, helping convert food into energy (ATP). It supports cellular energy production, particularly in high-energy tissues like the brain and muscles.
Nervous System Health
Thiamine is crucial for nerve function, supporting nerve signal transmission and myelin sheath maintenance. It may help prevent or manage nerve-related conditions like neuropathy, especially in cases of deficiency.
Brain Function
Thiamine supports cognitive health by aiding energy supply to brain cells. Deficiency is linked to neurological issues like Wernicke-Korsakoff syndrome (common in alcohol use disorder), and supplementation may improve memory and focus in deficient individuals.
Heart Health
Thiamine supports heart muscle function and may improve outcomes in heart failure patients with deficiency. It helps maintain proper cardiac energy metabolism.
Metabolic Disorders
Thiamine may benefit individuals with diabetes by improving glucose metabolism and reducing complications like diabetic neuropathy, though evidence is preliminary.
Digestive Health
Thiamine aids in producing stomach acid and supporting digestive enzyme function, potentially improving digestion and appetite in deficient individuals.
Mechanism of action
Coenzyme in Energy Metabolism
Thiamine pyrophosphate (TPP), the active form of thiamine, is a coenzyme for enzymes like pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase in the citric acid cycle, facilitating carbohydrate metabolism and ATP production.
Nerve Function
TPP supports nerve signal transmission by aiding sodium-potassium ATPase activity and maintaining myelin integrity, preventing nerve damage.
Glucose Regulation
Thiamine modulates glucose metabolism pathways, reducing oxidative stress and complications in conditions like diabetes.
Clinical trials
Two-center RCT (NCT01070810) in 88 patients with septic shock (lactate >3 mmol/L) receiving IV thiamine (200 mg twice daily) vs placebo. Outcomes: lactate clearance, mortality. (Donnino et al. 2016, Crit Care Med)
88 septic shock patients.
Modest signals on lactate clearance; mortality benefit in pre-specified thiamine-deficient subgroup. CRITICAL CONTEXT: subsequent VITAMINS, ATESS trials of thiamine + vitamin C + steroids (HAT protocol — Marik 2017) — large rigorous trials including the HYVCTTSSS multi-center RCT — were NEGATIVE for the metabolic resuscitation protocol. The Marik HAT protocol generated enthusiasm that did not survive rigorous validation.
Meta-analysis of 35 RCTs (n=3,494, through April 2023) evaluating IV thiamine (100-200 mg) in critically ill patients. (Tao et al. 2024, Clin Nutr)
Pooled across 35 critical care RCTs.
IV thiamine modestly improved lactate clearance and certain ICU outcomes. Mortality benefit not consistently observed. Note: thiamine deficiency is common in ICU populations (alcoholism, malnutrition, refeeding syndrome) — empiric thiamine in critically ill remains reasonable practice.
Multicenter RCT (ACTRN12619000121167) in 90 critically ill enterally fed patients receiving high-dose thiamine vs control. (Collie et al. 2021, Clin Nutr)
90 critically ill ICU patients.
Modest signals on certain biomarkers. ICU thiamine evidence base remains mixed; high-dose pharmacological thiamine is generally safe.
Phase 2a, single-site, randomized, double-blind, placebo-controlled pilot trial (Gibson et al. 2020) in mild-moderate AD patients receiving high-dose thiamine.
Pilot AD patients.
Modest signals on cognitive measures. CRITICAL CONTEXT: AD treatment landscape now includes lecanemab/donanemab (anti-amyloid antibodies, FDA-approved 2023-2024). Pharmacological thiamine has no established AD treatment role; pilot only.
RCT in 64 high-risk cardiac surgery patients undergoing CPB receiving high-dose thiamine vs placebo. Outcomes: lactate, postoperative outcomes. (Lomivorotov et al. 2020, J Cardiothorac Vasc Anesth)
64 cardiac surgery patients.
Modest signals on lactate during CPB. Cardiac surgery thiamine evidence still developing; not standard care.